We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
-0.39%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$2.25B
AUM Growth
-$167M
Cap. Flow
-$1.74M
Cap. Flow %
-0.08%
Top 10 Hldgs %
64.56%
Holding
59
New
8
Increased
7
Reduced
14
Closed
5

Top Buys

Rank Stock Value
1
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
+$90.7M
2
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$53.5M
3
OKUR
OnKure Therapeutics
OKUR
+$38.3M
4
VERV
Verve Therapeutics
VERV
+$32.9M
5
ABCL icon
AbCellera Biologics
ABCL
+$11.6M

Top Sells

Rank Stock Value
1
HRMY icon
Harmony Biosciences
HRMY
+$57.4M
2
INGN icon
Inogen
INGN
+$43M
3
CABO icon
Cable One
CABO
+$38.6M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$36.6M
5
EAR
Eargo, Inc. Common Stock
EAR
+$21M

Sector Composition

Rank Sector Weight
1 Healthcare 61.05%
2 Financials 7%
3 Technology 6.3%
4 Consumer Discretionary 2.54%
5 Communication Services 2.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FRLN
26
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$19.2M 0.85%
157,415
– –
IOVA icon
27
Iovance Biotherapeutics
IOVA
$2.83B
$17.6M 0.78%
675,160
+213,349
+46% +$5.55M
BPMC
28
DELISTED
Blueprint Medicines
BPMC
$17.3M 0.77%
197,000
– –
PRAX icon
29
Praxis Precision Medicines
PRAX
$10.1B
$16.6M 0.74%
60,697
-102,108
-63% -$36.6M
MIST icon
30
Milestone Pharmaceuticals
MIST
$152M
$13.9M 0.62%
2,530,585
– –
CMPI
31
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$12.9M 0.57%
2,170,100
– –
DMRA
32
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
$12.6M 0.56%
99,912
– –
FLXN
33
DELISTED
Flexion Therapeutics, Inc.
FLXN
$11.6M 0.51%
1,403,370
– –
LEGN icon
34
Legend Biotech
LEGN
$4.01B
$11.5M 0.51%
279,676
+25,500
+10% +$867K
TMCI icon
35
Treace Medical Concepts
TMCI
$309M
$10.1M 0.45%
+323,000
New +$10.3M
EAR
36
DELISTED
Eargo, Inc. Common Stock
EAR
$9.46M 0.42%
11,854
-25,000
-68% -$21M
ABCL icon
37
AbCellera Biologics
ABCL
$2.12B
$9.29M 0.41%
+422,382
New +$11.6M
INSP icon
38
Inspire Medical Systems
INSP
$1.74B
$8.92M 0.4%
46,151
+6,151
+15% +$1.22M
AERI
39
DELISTED
Aerie Pharmaceuticals
AERI
$8.89M 0.39%
555,186
-233,224
-30% -$4M
XENT
40
DELISTED
Intersect ENT, Inc
XENT
$8.7M 0.39%
508,922
– –
LUNG icon
41
Pulmonx
LUNG
$87.6M
$8.25M 0.37%
187,047
– –
ZGNX
42
DELISTED
Zogenix, Inc.
ZGNX
$7.65M 0.34%
442,550
+35,635
+9% +$656K
SILK
43
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$7.06M 0.31%
147,557
– –
KNTE
44
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$6.98M 0.31%
300,000
– –
NARI
45
DELISTED
Inari Medical, Inc. Common Stock
NARI
$6.74M 0.3%
72,212
– –
SPRO icon
46
Spero Therapeutics
SPRO
$73M
$6.55M 0.29%
468,902
– –
ALNY icon
47
Alnylam Pharmaceuticals
ALNY
$29.3B
$5.88M 0.26%
+34,679
New +$5.08M
AKUS
48
DELISTED
Akouos Inc
AKUS
$5.76M 0.26%
459,290
– –
BHVN
49
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$5.17M 0.23%
53,300
-75,000
-58% -$6.09M
VRNA
50
DELISTED
Verona Pharma
VRNA
$4.98M 0.22%
761,205
-77,155
-9% -$535K
1
2
3

Similar funds

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.24B AUM 16.52% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return
SPC
Stony Point Capital New York $1.24B AUM 32.69% 1-Year Est. Return
SC
Strategy Capital Los Altos, California $1.22B AUM 27.02% 1-Year Est. Return

Novo Holdings A/S's Q2 2021 Portfolio in Review

As of Q2 2021, Novo Holdings A/S held 59 positions worth $2.25B, down 6.9% from $2.42B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Novo Holdings A/S's Q2 2021 filing shows 8 new, 7 increased, 14 reduced and 5 closed positions. Its largest new stake was Cyteir Therapeutics, Inc. Common Stock: 4,840,413 shares worth $104M. The largest sale was Harmony Biosciences, an estimated $57.4M.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, down from 65% a quarter earlier, followed by Financials and Technology.

  • Novo Holdings A/S's largest Q2 2021 buy was Cyteir Therapeutics, Inc. Common Stock: 4,840,413 shares worth $104M.
  • Novo Holdings A/S added most to Insmed in Q2 2021, an estimated $7.1M increase.
  • Novo Holdings A/S's biggest Q2 2021 reduction was Harmony Biosciences, cutting an estimated $57.4M.
  • Novo Holdings A/S fully exited Constellation Pharmaceuticals, Inc. in Q2 2021, selling an estimated $16.4M.
  • Novo Holdings A/S's ten largest holdings make up 65% of its $2.25B portfolio in Q2 2021.
  • Novo Holdings A/S opened 8 new positions and closed 5 in Q2 2021.
  • Novo Holdings A/S's portfolio value fell 6.9% quarter-over-quarter to $2.25B.

Based on Novo Holdings A/S's 13F filing for Q2 2021, filed 16 Aug 2021.